







































































Virtual Active CD Population:							
<b>Data Incorporation (Simcyp Library)</b>							
Drug	Oral Formulation	Intestine Metabolising Enzyme/ Transporter *					
Celecoxib	Solution	CYP2C9 & CYP3A4					
Crizotinib	Immediate Release solid formulation	Сүрза4 & Р-др	Model	CD population			
Digoxin Dabigatran	Solution Solution	P-gp CES1, CES2 & P-gp	M-1	Intestine DMETs abundance from I-CD tissues and normal albumin level			
etexilate Gemfibrozil	Solution	UGT2B7	M-2	Intestine DMETs abundance from I-CD tissues and reduced albumin level			
Ritonavir	Immediate Release solid formulation	CYP2D6, CYP3A4 & CYP3A5	M-3	Intestine DMETs abundance from HN- CD tissues and normal albumin level			
Rosuvastatin Valsartan	Solution Immediate Release solid	BCRP & OATP2B1 CYP2C9 & MRP2	M-4	Intestine DMETs abundance from HN- CD tissues and reduced albumin level			
Verapamil	formulation Solution	CYP2C8, CYP3A4, CYP3A5, P-gp & MRP2					
* based on the inco protein mentioned bound to the drug	prporated enzymes and transporters is based on what Simcyp drug profi	Linnuhliched results					















<b>BE Criteria and Coloring Rule</b> For 10 trials simulation, if more than or equal to 8 of 10 trials show bioequivalence, the formulation will be defined as BE.							
		Plasma	Local				
	True positive	BE	BE				
	False positive	BE	NBE				
	True negative	NBE	NBE				
	False negative	NBE	BE				
				39			





